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Abstract: Bazedoxifene acetate is a novel, chemically distinct selective estrogen receptor 
modulator (SERM) that has been speciﬁ  cally developed after a stringent preclinical screening 
in order to obtain favorable effects on the skeleton and lipid metabolism with the additional 
improvement of a neutral effect on hot ﬂ  ushes and without stimulating the uterus or the breast. In 
both preclinical and clinical studies this SERM was shown to maintain BMD, prevent fractures, 
and reduce total cholesterol. Moreover, bazedoxifene also showed an improved uterine proﬁ  le 
and demonstrated estrogen antagonistic activity on the endometrium. Importantly, this latter 
capacity has led to the development of a novel class of menopausal therapy called tissue selec-
tive estrogen complex (TSEC), in which bazedoxifene is combined with conjugated estrogen. 
The rationale for selecting bazedoxifene as the SERM in this TSEC combination is that it may 
offset estrogen stimulation of endometrial and breast tissue, without the necessity of using a 
progestin in women with an intact uterus, without aggravating menopausal vasomotor symp-
toms, but with an additive effect on bone. Preliminary data from phase 3 clinical trials appear 
to conﬁ  rm this hypothesis, showing a greater effect of bazedoxifene on BMD with respect to 
raloxifene, coupled with efﬁ  cacy on menopausal vasomotor symptoms not achieved by SERM 
alone. These properties and the safety proﬁ  le of this combination, if conﬁ  rmed long-term in 
ongoing phase 3 trials, might signiﬁ  cantly affect the way women and physicians approach 
menopause and its related disorders.
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Introduction
Osteoporosis
Osteoporosis is a skeletal disorder characterized by compromised bone strength 
and increased risk of fracture (Osteoporosis Prevention, Diagnosis, and Therapy 
Consensus Statement 2000). It is one of the most common disorders in elderly subjects 
and represents a major public health problem, affecting up to 40% postmenopausal 
women and 15% of men. Its clinical signiﬁ  cance lies in the occurrence of fractures, 
involving most commonly the forearm, the vertebral bodies and the hip, but fractures 
at other sites may be also associated with the disease. It has been estimated that in 
the US, at least 90% of all hip and spine fractures among elderly white women and 
more than 70 % of those among elderly white men may be attributed to osteoporosis 
(Melton et al 1997). The occurrence of osteoporotic fractures leads to considerable 
mortality, morbidity, reduced mobility and decreased quality of life. Fractures of the 
hip incur the largest direct cost for health services, giving rise to substantial morbidity 
and mortality (Center et al 1999). Osteoporotic fractures of the vertebrae are of less 
economic signiﬁ  cance, but also give rise to signiﬁ  cant morbidity, causing back pain, 
disability, kyphosis and height loss (Barrett-Connor 1995). Moreover, future risk 
of osteoporotic fractures is greatly increased in patients with one or more vertebral 
fractures and quality of life becomes progressively impaired as the number and Therapeutics and Clinical Risk Management 2008:4(6) 1230
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severity of vertebral fractures increases (Melton et al 1999). 
In 1999, the annual number of hip fractures in 15 countries of 
EC has been estimated to be 500,000, with a total care cost of 
about €4.8 billion per year (International Osteoporosis Foun-
dation 1999). In US alone, in 2005 there were over 2 million 
osteoporosis-related fractures, with direct healthcare costs 
of nearly US$17 billion (Burge et al 2007). This burden is 
increasing annually in absolute terms because of the ageing 
of the population (Cooper et al 1992). Given the magnitude 
of the problem, the prevention and treatment of osteoporosis 
is, therefore, of major importance for health organizations 
in all countries. The major determinant of bone strength and 
osteoporotic fracture risk is bone mineral density (BMD), 
as assessed by dual photon absorptiometry (DPA) or dual 
energy x-ray absorptiometry (DXA). According to WHO 
criteria, osteoporosis is deﬁ  ned to exist when BMD values 
fall more than 2.5 standard deviations below the young adult 
reference mean (Osteoporosis Prevention, Diagnosis, and 
Therapy Consensus Statement 2000). Many studies indicated 
that the risk of fragility fractures increases progressively as 
BMD declines (Cummings et al 1990; Cummings et al 1993; 
Black et al 1992; Hui et al 1995). However, bone strength 
depends not only on BMD. Bone size as well as bone quality 
are other important components that interact with BMD in 
determining the risk of fracture.
Estrogen deﬁ  ciency and physiopathology 
of osteoporosis
In women, osteoporosis and fractures mainly occur as a 
consequence of estrogen deﬁ  ciency after menopause and 
result from an imbalance between bone resorption by 
osteoclasts and bone formation by osteoblasts, leading to 
a net bone loss with each remodeling cycle. A decrease in 
estrogen production from androgen precursors has also been 
supposed to be a major cause of bone loss and osteoporosis 
in aging men (Riggs et al 1998; Khosla et al 2002; Gennari 
et al 2004). To date, the mechanism by which estrogen 
affects bone metabolism is complex and not fully elucidated. 
Possible mechanisms include a decrease in osteoclastogen-
esis, osteoclast apoptosis and additional effects on calcium 
homeostasis (Riggs et al 1998; Riggs et al 2002). Estrogen 
acts through the binding and activation to estrogen receptor 
α (ERα) and β (ERβ). While both the ERs bind estrogen 
as well as other agonists or antagonists (even though with 
different afﬁ  nities), they have distinctly different localiza-
tions and concentrations in several tissues, including bone 
(Gustafsson 1999; Bord et al 2001). In fact, concentrations 
of ERβ are higher in developing cancellous bone, whereas 
concentrations of ERα are higher in developing cortical bone 
(Bord et al 2001). Moreover, target cells for estrogen action 
may contain varying concentrations of homodimers of one or 
both ERs, as well as ERα and ERβ heterodimers. Structural 
functional differences also exist between ERα and ERβ, 
when complexed with estrogen, allowing for a wide range 
of diverse actions to take place. Importantly, the decrease in 
estrogen production during menopause has been associated 
with other nonskeletal complications in women involving 
lipid metabolism, and the cardiovascular and nervous 
systems. A decrease in estrogen level has been also associated 
with menopausal vasomotor symptoms, such as hot ﬂ  ushes, 
insomnia, nausea and vaginal discharge or bleeding.
Treatment options for osteoporosis
Among the several therapeutic interventions in osteoporosis, 
hormone replacement therapy (HRT) has traditionally been 
seen as the gold standard method of preventing fractures 
in postmenopausal women, as well as for the management 
of menopausal symptoms. However, despite both in vivo 
and in vitro biologically plausible mechanisms for cardiac 
protection by estrogen and observational studies indicating 
that HRT confers cardiovascular protection, the Women’s 
Health Initiative (WHI) and other recent randomized, con-
trolled trials have failed to conﬁ  rm any potential beneﬁ  t 
in reducing the risk of coronary artery disease and stroke 
(Manson et al 2003). Indeed, early increases in cardiac event 
and stroke rate have been seen in women taking combina-
tion HRT. Moreover, HRT, especially if long term, leads 
to an increased risk of breast cancer and, when unopposed 
by progestins, endometrial cancer (Vassilopoulou-Sellin 
2003). Other side effects often associated with HRT are 
ﬂ  uid retention, breast pain, headache and resumption of 
menstrual cycle. Thus, in many countries the use of HRT is 
actually limited to a short-term (5 years or less) treatment 
of menopausal symptom. In contrast, estrogen therapy must 
be long-term, possibly lifelong, to have any lasting impact 
on bone health. Alternative therapies for the prevention 
and the treatment of osteoporosis include bisphosphonates, 
calcitonin, vitamin D and its active metabolites, selective 
estrogen receptor modulators (SERMs), strontium ranelate 
and parathyroid hormone.
SERMS for prevention and treatment 
of osteoporosis
SERMs are a class of compounds that can act as ER agonists 
in some tissues while acting as ER antagonists in others 
(Cho and Nuttall 2001). They include chemically diverse Therapeutics and Clinical Risk Management 2008:4(6) 1231
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molecules that lack the steroid structure of estrogens, but 
possess a tertiary structure that allows them to bind to 
ERα and/or ERβ. Most of the unique pharmacology of 
SERMs as well as their agonistic and antagonistic activity 
on estrogen target tissues can be explained by 3 main inter-
active mechanisms (Riggs and Hartmann 2003): differential 
ERα and ERβ expression, differential ER conformation on 
ligand binding, and differential expression and binding to 
the ER of coregulator proteins (coactivators or corepres-
sors). Because of their selective estrogen-agonist properties 
on different target tissues SERMs can be indicated for the 
prevention or treatment of diseases caused by estrogen 
deﬁ  ciency, including osteoporosis, without most of the 
undesiderable effects of estrogens. In addition, due to their 
selective estrogen-antagonist properties in the breast, SERMs 
can be also used to prevent or treat breast cancer, in which 
estrogen-agonistic activity is undesiderable.
Currently there are two main chemical classes of SERMs 
approved for clinical use: the triphenylethylene derivatives 
tamoxifen and toremifene that are used to treat breast can-
cer, and raloxifene, a benzothiopene derivative indicated 
for the treatment and prevention of osteoporosis (Cho and 
Nuttall 2001; Morello et al 2002; Gennari et al 2007) and in 
the US for breast cancer risk reduction (Vogel et al 2006; 
Gennari et al 2008). All three also have beneﬁ  cial effects 
on serum lipids, but are associated with venous thrombo-
embolism and hot ﬂ  ushes. Moreover, although tamoxifen 
has a positive effect on bone as well, the increased risk of 
endometrial cancer eliminates it as a possible therapy for 
postmenopausal osteoporosis. The effects of raloxifene on 
bone are well established. Clinical trials demonstrated that at 
a daily dose of 60 mg is effective in the prevention and treat-
ment of postmenopausal osteoporosis (Delmas et al 1997; 
Lufkin et al 1998; Ettinger et al 1999). This compound also 
lacks estrogenic activity at the uterus but is associated with 
adverse effects such as blood clots and vasomotor symptoms, 
including hot ﬂ  ushes. In addition, both preclinical and clinical 
reports suggested that both tamoxifen and raloxifene are 
considerably less potent than estrogen (Prestwood et al 2000; 
Weinstein et al 2003), in part due to their reduced bioavail-
ability. Moreover, even though raloxifene treatment was able 
to prevent bone loss and the occurrence of vertebral fractures, 
its effect in the prevention of hip fractures is still uncertain. 
Actually, the beneﬁ  ts of these SERMs in reducing the risks 
of invasive breast cancer and vertebral fracture should be 
weighed against the increased risks of venous thromboem-
bolism, fatal stroke, and in case of tamoxifen, uterine cancer. 
Moreover, up to 50% of women taking available SERMs for 
different indications reported moderate or severe vasomotor 
or gynecologic symptoms (especially vaginal dryness and 
hot ﬂ  ushes) that could hinder compliance. It is evident that 
there is a need for a SERM that has the desiderable tissue 
speciﬁ  c estrogenic and antiestrogenic actions with minimal 
side effects.
Bazedoxifene is potent new generation SERM, being 
developed to be used alone for the prevention and treatment 
of osteoporosis in postmenopausal women and in combina-
tion with conjugated equine estrogens for menopausal symp-
toms and prevention of postmenopausal osteoporosis (Gruber 
and Gruber 2004; Gennari et al 2007; Lewiecki 2007; Stump 
et al 2007). In this article the available published data about 
mechanism of action, dosing, pharmacokinetics and toxicity 
of this new SERM are reviewed.
Chemistry, metabolism 
and pharmacokinetic proﬁ  le
Bazedoxifene acetate (WAY-140424, TSE-424) is an 
indole-based ER ligand with unique structural characteristics 
with respect to raloxifene and tamoxifen (Figure 1), and 
stringently selected to ensure an improved proﬁ  le versus 
its predecessors (Komm and Lyttle 2001; Miller et al 2001; 
Komm et al 2005). The molecule was assembled by using 
raloxifene as a template and substituting an indole ring for 
the benzothioprine core (Gruber and Gruber 2004). The 
side chain of bazedoxifene is synthesized by alkylation of a 
4-hydroxy benzyl alcohol with ethyl bromoacetate, followed 
by conversion of the alcohol to benzyl chloride with SOCl2 
in tetrahydrofuran. Alkylation is achieved with NaH in 
dimethyl formamide, which yields an ester that is subse-
quently reduced with lithium aluminum hydride. The primary 
alcohol is converted to a bromide with carbon tetrabromide 
and triphenylphosphine. The bromide is then substituted with 
hexamethylenimine and the product is hydrogenated and 
converted to the acetate salt (1-[4-(2-azepan-1-yl-ethoxy)-
benzyl]-2-(4-hydr- oxy-phenyl)-3-methyl-1H-indol-5-ol 
acetic acid, bazedoxifene).
Bazedoxifene exerts signiﬁ  cant estrogenic and anti-
estrogenic activity, both in vitro and in vivo, targeting any 
tissues that possess ERs, such as bone, uterus, breast, blood 
vessels, and liver. This SERM binds to both ERα and ERβ‚ 
with a slight higher afﬁ  nity for ERα. However, it is less ERα 
selective than raloxifene, with an afﬁ  nity for ERα (IC50 of 
26 nM) that is about 10-fold lower than 17β-estradiol (Miller 
et al 2001; Komm et al 2005). The dissociation constant for 
bazedoxifene is about 0.1 nM for ERα and 0.3 nM for ERβ 
(Stump et al 2007).Therapeutics and Clinical Risk Management 2008:4(6) 1232
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The absolute and relative bioavailability of bazedoxifene 
was assessed in an open-label, randomized, three-way 
crossover study conducted in healthy postmenopausal women 
(n = 18) under fasting conditions (Patat et al 2003). The 
two oral formulations (a 10-mg tablet and a 5-mg capsule) 
were bioequivalent with respect to AUC and the concentration-
time proﬁ  les. The absolute bioavailability of  both formulations 
was approximately 6.2%, which is 3-fold the bioavailabil-
ity of other SERMs. The metabolism of a single dose of 
[14C]bazedoxifene (20 mg) was evaluated in a different study 
in 6 healthy, postmenopausal women (Chandrasekaran et al 
2003). Blood, urine and feces were analyzed for radioactivity 
for 10 days. The major route of excretion was in the feces 
(84.7%), with only a minor fraction (0.81%) excreted in the 
urine. The major metabolic pathway was glucuronidation, with 
40%–95% of metabolites being bazedoxifene-5-glucuronide. 
Moreover, there was little or no cytochrome P450 metabolism. 
To evaluate the pharmacokinetic and pharmacodynamic proﬁ  le 
of bazedoxifene, a preliminary study with different oral doses 
(1, 2.5, 5, 10, 20, 40, and 80 mg) was conducted for 30 days 
in 12 healthy postmenopausal women per cohort (Ermer et al 
2000). Plasma concentrations increased in a linear fashion 
with a steady-state obtained by day 14. From the study it was 
also anticipated that a 500 pg/ml plasma concentration may 
be necessary to produce a therapeutic effect. This concentration 
was achieved by both 5 and 10 mg daily regimens, suggesting 
that these will provide efﬁ  cacious effects in phase 2 and 
phase 3 studies. In a subsequent randomized, crossover, dose 
proportionality study different oral doses of bazedoxifene 
(5, 20, or 40 mg) were given over 14 days in 23 postmenopausal 
women with a range of  body weights from 53 to 79 kg (Ermer 
et al 2003). The drug showed a linear pharmacokinetics in the 
dose range tested, with maximum plasma concentration (Cmax) 
achieved 1–2 hours after dosing and a serum half-life (t1/2) of 
about 28 hours. Protein binding was greater than 99%, and 
the steady-state plasma concentration was achieved by day 7, 
without unexpected drug accumulation.
Since bazedoxifene is metabolized by glucuronidation (as 
many other compounds), an open-label, randomized, 3-way 
crossover study in 12 healthy postmenopausal women was 
conducted to evaluate for possible drug-drug interactions 
between bazedoxifene and ibuprofen, a commonly used 
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Figure 1 Chemical structure of estradiol, bazedoxifene, and other currently approved SERMS.Therapeutics and Clinical Risk Management 2008:4(6) 1233
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non-prescription nonsteroidal anti-inﬂ  ammatory drug (Baird 
et al 2002). No signiﬁ  cant interaction was observed, indi-
cating that both drugs may be safely administered together 
without the need of dosage adjustment.
Preclinical studies
The preclinical data supporting bazedoxifene as an anti-
resorptive therapy for the prevention and treatment of 
postmenopausal osteoporosis are well documented. Several 
in vitro and in vivo experimental observations demon-
strated that bazedoxifene interacts with both ERs inducing 
receptor transactivation and positively affecting the skeleton 
and the lipid proﬁ  le without stimulating the endometrium 
and the breast or negatively impacting the central nervous 
system.
Preclinical efﬁ  cacy of bazedoxifene 
on bone
In different studies in OVX rat model, bazedoxifene was 
effective in maintaining bone mass at a dose as low as 
0.1 mg/kg/day, reaching maximal signiﬁ  cant efﬁ  cacy at a 
dose of 0.3 mg/kg/day (Komm and Lyttle 2001; Miller et al 
2001; Komm et al 2005). Moreover, this dose maintained 
vertebral compressive strength (a surrogate for a reduced 
incidence of fracture) equivalent or better than the sham 
operated animals (Komm et al 2005). The histological quality 
of bone (assessed at the proximal tibia) was maintained and 
correlated well with the increases in BMD and compressive 
force data. In particular, bazedoxifene treatment prevented 
the loss in trabecular bone, and the increase in osteoclast 
number induced by ovariectomy, without affecting dynamic 
parameters of bone formation compared with sham operated 
animals (Komm et al 2005). Efficacy on most skeletal 
parameters appeared to be similar to other SERMs such as 
raloxifene and lasofoxifene (Black et al 1994; Ke et al 1998; 
Gennari et al 2007). Interestingly, in a more recent study in 
OVX monkeys, bazedoxifene treatment at dose levels up to 
25 mg/kg/day for 18 months resulted in the partial preser-
vation of bone mass (as determined by bone densitometry) 
and strength and in a signiﬁ  cant prevention of OVX-induced 
increases in bone turnover (evaluated by biochemical markers 
and histomorphometric indices in cancellous and cortical 
bone) (Smith et al 2005).
A different study in OVX mice evaluated the ability of 
lasofoxifene 0.1 mg/kg/day, bazedoxifene 0.3 mg/kg/day and 
raloxifene 3 mg/kg/day or risedronate 1 mg/kg/day to enhance 
reversal of established osteopenia when co-administered with 
human PTH (hPTH) 10 mcg/kg/day s.c. After 4 weeks of 
treatment, total and trabecular BMD were 3%–10% higher 
in all of the cotreatment groups compared with the hPTH 
monotherapy group (Kharode et al 2003).
Preclinical safety of bazedoxifene
In all preclinical in vivo studies, bazedoxifene was well 
tolerated and was not associated with any adverse effects 
on plasma lipids or reproductive tract histology. Moreover, 
similar to raloxifene, bazedoxifene dose-dependently 
inhibited estrogen-induced MCF-7 breast cancer cell 
proliferation (Komm et al 2005). These data do not address 
the inﬂ  uence of this compound on normal mammary gland, 
but preliminary data in a rat mammary gland differentiation 
model showed that bazedoxifene does not act as estrogen, 
resulting in no detectable histological response (Komm 
et al 2003a). Importantly, an improved preclinical uterine 
proﬁ  le of bazedoxifene over raloxifene was demonstrated. 
In fact, in the OVX mice model, bazedoxifene did not 
induce any change in uterine wet weight compared with 
OVX vehicle-treated animals, while raloxifene treatment 
signiﬁ  cantly affected uterine wet weight. This difference 
was conﬁ  rmed in a different and more sensitive preclinical 
model, the 3-day immature rat uterine model (Komm 
et al 2005). In these mice bazedoxifene produced a 35% 
increase in uterine wet weight at 0.5 mg/kg dose, but 
did not induce any change at a higher (5.0 mg/kg) dose. 
In contrast, raloxifene at equivalent treatment dosages 
signiﬁ  cantly increased uterine weight by 75.9%–85.2%. 
Histological examination of the entire uterus showed 
that bazedoxifene does not affect luminal epithelial cell 
hypertrophy or hyperplasia, myometrial hypertrophy, or 
luminal distention. Moreover, in the same model, co-
treatment of bazedoxifene with raloxifene completely 
abrogated raloxifene-induced increase in myometrial or 
luminal epithelial cell hypertrophy, further supporting an 
improved uterine proﬁ  le of bazedoxifene.
Potential effects of  bazedoxifene on vasomotor reactivity 
and thermoregulation were also evaluated in a preclinical 
study using morphine-addicted rat model. This model 
represents an experimental paradigm designed to evaluate 
thermoregulatory response initiated by a naloxone injection to 
morphine-addicted animals (Katovitch et al 1986). Naloxone-
induced increase in tail skin temperature is ablated in rats 
pretreated with estradiol. In this animal model bazedoxifene 
alone, like raloxifene, did not act as estrogen agonist and did 
not blunt the thermoregulatory response to naloxone (Komm 
et al 2005). However, in contrast to raloxifene, no antagonism 
was observed when bazedoxifene was co-administered with Therapeutics and Clinical Risk Management 2008:4(6) 1234
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17β-estradiol at bone sparing efﬁ  cacious doses (0.3 mg/kg). 
This suggested a potential lack of vasomotor effect of 
bazedoxifene in postmenopausal women. A different study 
indicated that bazedoxifene seems to maintain or increase 
nitric oxide synthase activity, implying a possible positive 
regulation of atherogenic processes, including monocyte 
adhesion, platelet aggregation, vascular smooth muscle cell 
proliferation and vasoconstriction (Wassmann et al 2002). 
Concerning this aspect, an increased effect on endothelial 
nitric oxide synthase activity has been reported in comparison 
with raloxifene.
Importantly, preclinical combination studies in OVX 
mice have been conducted to evaluate the effect of 
bazedoxifene when administered alongside conjugated 
estrogens (Premarin) or hPTH. At doses 7- to 10-fold higher 
than the bone efﬁ  cacious dose, bazedoxifene antagonized 
the uterine stimulation of Premarin, without differences 
to untreated OVX controls. In contrast, positive skeletal 
effects were maintained, since OVX mice co-dosed with 
bazedoxifene 3 mg/kg/day and Premarin 2.5 mg/kg/day 
demonstrated BMD and cancellous bone compartments 
that were similar to sham-operated animals (Komm et al 
2003a). A similar study compared the effects of the addi-
tion of different SERMs (raloxifene, bazedoxifene, and 
lasofoxifene) to the bone efﬁ  cacious dose of conjugated 
estrogens. Even though no differences in skeletal parameters 
were noted for the 3 groups, only bazedoxifene was able to 
antagonize the effect of conjugated estrogen on uterine wet 
weight (Komm et al 2003b).
Summary of preclinical evaluation 
of bazedoxifene
Overall, preclinical data indicated that bazedoxifene (given 
either alone or in combination with conjugate estrogen) may 
represent a promising new treatment for osteoporosis, with a 
potential for less uterine and vasomotor effects than SERMs 
currently used in clinical practice. Like the other SERMs, in 
the tested OVX models the skeletal response in term of  BMD 
gain appears lower than 17β-estradiol or bisphosphonates, 
but probably sufﬁ  cient to result in a signiﬁ  cant increase in 
bone strength.
Clinical studies
Notwithstanding the encouraging preclinical evidences, 
clinical available data on bazedoxifene treatment are limited. 
Several phase I trials have been conducted in healthy post-
menopausal women to study the metabolism and pharma-
cokinetics of the compound, with no signiﬁ  cant adverse 
effects (Morii 2000; Ermer et al 2000; Chandrasekaran 
et al 2003; Ermer et al 2003; Patat et al 2003; Gruber and 
Gruber 2004). Consistent with preclinical observations, in a 
preliminary 30-day study in healthy postmenopausal women, 
a signiﬁ  cant 21% decrease in a marker of bone resorption 
(collagen C-link N-telopeptide) was observed (Ermer et al 
2000). At daily doses ranging from 1 to 80 mg, a decrease 
in ﬁ  brinogen levels and no increase in vasomotor symptoms 
were also reported.
Phase II studies of bazedoxifene acetate
The preliminary efﬁ  cacy and safety of 6 different doses 
of bazedoxifene in healthy postmenopausal women with 
increased bone turnover (deﬁ  ned as urinary N-terminal 
cross-linked telopeptides of type I collagen  30 nmol /mmol 
creatinine) was tested in a phase II, 6-month, single-center, 
double-blind, randomized, active- and placebo-controlled 
study (Ronkin et al 2001; Ronkin et al 2005; Boudes et al 
2003). This study was conducted in two parts. Part I studied 
4 daily doses of bazedoxifene (2.5 mg, 5 mg, 10 mg, and 
20 mg), with respect to placebo or conjugated estrogens 
plus medroxyprogesterone acetate 0.625/2.5 mg. Because of 
favorable results, the trial was extended to study additional 
doses for part II, which subsequently enrolled women not 
previously randomized in part I, to 3 daily doses of baze-
doxifene (20 mg, 30 mg, and 40 mg) or placebo. A total 
of 360 women were enrolled in Part I and 240 in Part II. 
All women also received supplemental calcium carbonate 
600 mg/day. In part I of the study, bazedoxifene at 2.5 to 
20 mg/day resulted in mean changes from baseline in self 
reported breast density and endometrial thickness that were 
not signiﬁ  cantly different from placebo group. As expected, 
treatment with conjugated estrogens/medroxyprogesterone 
acetate resulted in a small but signiﬁ  cant increase in endo-
metrial thickness and breast pain compared with placebo 
(Ronkin et al 2001; Ronkin et al 2005). These positive 
results of bazedoxifene were conﬁ  rmed in part II of the 
study. Interestingly, a statistically signiﬁ  cant decrease in 
endometrial thickness relative to placebo was observed 
for both the 30- and 40-mg bazedoxifene dose. Regression 
analysis showed that bazedoxifene doses were inversely 
related to the change from baseline in endometrial thick-
ness, suggesting greater endometrial antagonism as the dose 
of bazedoxifene increased. Moreover, the 40 mg dose was 
also associated with a signiﬁ  cant decrease in breast pain 
compared with placebo (Boudes et al 2003). At the skeleton, 
bazedoxifene produced a dose-dependent reduction of bone 
turnover markers compared with placebo at doses as low as Therapeutics and Clinical Risk Management 2008:4(6) 1235
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5 mg/day (Ronkin et al 2001). When administered at doses of 
20 or 40 mg, bazedoxifene reduced bone turnover by 20 and 
26%, respectively.
A different randomized, double-blind phase II study of 
bazedoxifene versus placebo for the evaluation of BMD in 
375 Japanese patients with postmenopausal osteoporosis 
has been recently completed. No data have been released 
from this study.
Phase III studies of bazedoxifene acetate
phase III trials of bazedoxifene for postmenopausal 
osteoporosis had begun by October 2001 (Table 1), with 
over 10.000 women included worldwide. A ﬁ  rst 2-year, 
multicenter, double-blind, randomized trial compared the 
efﬁ  cacy of 3 bazedoxifene doses (10, 20, or 40 mg) with 
placebo and raloxifene (60 mg) in 1434 postmenopausal 
women with osteopenia (BMD T score at the lumbar spine 
or femoral neck between –1.0 or –2.5) or clinical risk factors 
for osteoporosis (Miller et al 2007; Miller et al 2008). The 
primary endpoint was the percent BMD change at the lumbar 
spine at 24 months compared to placebo. Secondary end-
points included BMD change at the hip (total hip, femoral 
neck, and trochanter BMD at 6, 12, 18, and 24 months), 
bone turnover marker change (serum osteocalcin and type 1 
collagen C-telopeptide at 3, 6, 9, 12, 18, and 24 months), and 
lipid changes at 3, 6, 12, 18, and 24 months. All doses of baze-
doxifene and raloxifene prevented bone loss compared with 
placebo after 24 months of treatment. Mean differences in 
percent lumbar BMD change at 24 months relative to placebo 
were 1.08%, 1.41%, 1.49%, and 1.49% for bazedoxifene 
10, 20, and 40 mg and raloxifene 60 mg, respectively. The 
differences in response between the bazedoxifene doses and 
between bazedoxifene and raloxifene were not statistically 
signiﬁ  cant. However, only women receiving bazedoxifene 
40 mg experienced a signiﬁ  cant increase from baseline 
in lumbar BMD at 6 and 12 months. Comparable BMD 
responses were observed with bazedoxifene and raloxifene 
at the femoral sites. Moreover, signiﬁ  cant decreases in serum 
osteocalcin and type 1 collagen C-telopeptide levels from 
baseline and relative to placebo were observed with all active 
treatments as early as 3 months and were sustained through-
out the study. A decrease in total and LDL cholesterol was 
also observed with bazedoxifene and raloxifene compared 
with placebo.
A different phase III, multicenter, double-blind, 
randomized, placebo-controlled study was specifically 
designed to evaluate the efficacy of bazedoxifene for 
the prevention of fractures (Silverman et al 2008). The 
study enrolled 7492 healthy postmenopausal women with 
osteoporosis with or without prevalent vertebral fractures. 
Participants were randomized to receive bazedoxifene 
(20 or 40 mg/day), raloxifene (60 mg), or placebo and 
calcium (1200 mg) plus vitamin D (400 IU) supplementation. 
The primary endpoint was the incidence of new vertebral 
fractures after 36 months. Secondary outcomes included 
breast cancer incidence, clinical vertebral fractures, wors-
ening vertebral fractures, nonvertebral fractures, and height 
changes. Both bazedoxifene doses prevented the incidence of 
vertebral fractures relative to placebo, with a similar efﬁ  cacy 
as raloxifene. The 3-year incidence of new vertebral fractures 
Table 1 Clinical phase III trials of bazedoxifene in osteoporosis
Protocol ID 
(date started)
Population (n) Compound Primary endpoints Secondary endpoints
NCT004811691 
( July 2001)
Caucasian 
postmenopausal 
women (n = 1583; 
BMD available for 
1434)
BAZ 10, 20, 40 mg vs 
Raloxifene 60 mg or 
Placebo (+ calcium 
600 mg)
Lumbar BMD change at 2 years Femoral BMD change at 6, 12, 18, 
24 months; lipid proﬁ  le and bone 
markers
NCT002057772 
(October 2001)
Caucasian 
postmenopausal 
women (n = 7492)
BAZ 20, 40 mg vs 
Raloxifene 60 mg or 
placebo (+ calcium 
1200 mg and vitamin D
400 IU)
Incidence reduction of new 
vertebral fractures at 3 years; 
safety proﬁ  le
Breast cancer incidence; clinical 
vertebral fractures; worsening 
vertebral fractures; nonvertebral 
fractures; height changes
NCT003840723 
(May 2006)
Asian postmeno-
pausal women 
(target n = 500)
BAZ 20 mg vs placebo Lumbar BMD change after 
6 months
Femoral BMD change at 
6 months; bone markers and lipid 
proﬁ  le at 3 and 6 months
1A multicenter, double-blind, randomized, placebo and raloxifene controlled study to assess the safety and efﬁ  cacy of TSE-424 (bazedoxifene acetate) in the prevention of 
postmenopausal osteoporosis; 2Fracture incidence reduction and safety of TSE-424 (bazedoxifene acetate) compared to placebo and raloxifene in osteoporotic postmenopausal 
women; 3A multicenter, double-blind, randomized, placebo-controlled study to assess the safety and efﬁ  cacy of bazedoxifene in postmenopausal Asian women.
Abbreviation: BMD, bone mineral density.Therapeutics and Clinical Risk Management 2008:4(6) 1236
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were 2.3%, 2.5%, 2.3%, and 4.1% in the bazedoxifene 20 mg, 
bazedoxifene 40 mg, raloxifene 60 mg, and placebo groups, 
respectively, with a signiﬁ  cant relative risk reduction for 
new vertebral fracture of 42%, 37%, and 42%, respectively, 
versus placebo (Figure 2a). There was overall no treatment 
effect on non-vertebral fractures, with incidence rates of 
5.7% and 5.6% for the bazedoxifene 20- and 40-mg treatment 
groups, respectively, compared with 5.9% for the raloxifene 
treatment group and 6.3% for the placebo group (Figure 2a). 
However, in a post-hoc analysis of women with higher risk 
for fractures (low femoral neck T-score and multiple vertebral 
fractures, n = 1,772) bazedoxifene 20 mg showed a 50% and 
44% reduction in the risk of nonvertebral fracture compared 
with placebo (HR = 0.50; 95% CI, 0.28–0.90; p = 0.02; ) or 
raloxifene 60 mg (HR = 0.56; 95% CI, 0.31–1.01; p = 0.05), 
respectively (Silverman et al 2008) (Figure 2b). A similar 
but not signiﬁ  cant trend for reduced nonvertebral fracture 
incidence was also observed with bazedoxifene 40 mg.
Another multicenter, double-blind, randomized, phase III 
trial was designed to evaluate the percent change in lumbar 
spine BMD compared with baseline after 6 months of treat-
ment with bazedoxifene 20 mg/day or placebo in postmeno-
pausal Asian women. Secondary efﬁ  cacy outcomes were 
BMD at femoral sites, serum bone markers at 3 and 6 months 
or lipid proﬁ  le. Participants were healthy Asian women who 
were 1–5 years postmenopausal with at least 1 osteoporosis 
clinical risk factor, or at least 5 years postmenopausal with 
a T-score at the lumbar spine between –1.0 and –2.5 and 
at least 1 osteoporosis clinical risk factor. The study was 
completed in September 2007, but no data have been released 
[http://www.clinicaltrials.gov/ct/action/GetStudy].
Clinical studies of bazedoxifene acetate 
in combination with estrogen
Following the positive preclinical observation in the OVX 
mice model (Komm et al 2003a) and given its unique anties-
trogenic action on the endometrium, speciﬁ  c trials have been 
designed to evaluate efﬁ  cacy and safety proﬁ  le of bazedoxi-
fene combined with conjugate estrogen (bazedoxifene /CE). 
The rationale for selecting bazedoxifene as the SERM in 
this combination is that it may offset estrogen stimulation 
of endometrial and breast tissue, without the necessity of 
using a progestin in women with an intact uterus or aggra-
vating menopausal vasomotor symptoms, while stabilizing 
or increasing BMD (Gruber and Gruber 2004; Lewiecki 
2007; Stump et al 2007). This combination of a SERM with 
conjugated estrogen has lead to a new class of menopausal 
therapy called “tissue selective estrogen complex (TSEC)” 
(Bergmann Koury 2007; Komm et al 2007; Stovall and 
Pinkerton 2008).
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Figure 2 Percentage of incident fractures after 3 years of bazedoxifene acetate (BZA, 20 and 40 mg) treatment compared with raloxifene 60 mg (RAL) and placebo (PB) in 
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In phase II clinical trials several dose combinations of 
bazedoxifene/CE were tested with respect to bazedoxifene 
alone, conjugated estrogen or placebo in healthy postmeno-
pausal women (Lewiecki 2007). A multicenter, randomized, 
double-blind, controlled pilot study explored the safety 
and efﬁ  cacy of 6 doses of bazedoxifene/CE (bazedoxifene 
5, 10, or 20 mg combined with CE 0.3 or 0.625 mg) with 
respect to placebo, CE (0.3 and 0.625 mg), CE 0.625 mg 
with medroxyprogesterone acetate 2.5 mg, and bazedoxifene 
5 mg alone (Van Duren et al 2006). The primary outcome 
was endometrial thickness as measured by transvaginal 
ultrasound at the end of the study (day 84). Other endpoints 
included hot flushes and the incidence of amenorrhea. 
Participants were 408 healthy postmenopausal women, with 
endometrial thickness less than 5 mm, and an average of at 
least 4 hot ﬂ  ushes per day. As expected CE alone increased 
endometrial thickness. However, the addition of bazedoxi-
fene to CE resulted in a dose-related decrease in endometrial 
thickness. At day 84, a statistically signiﬁ  cant lower increase 
in endometrial thickness was observed in the bazedoxifene 
20 mg/CE 0.3 mg, bazedoxifene 10 mg/CE 0.625 mg, and in 
the bazedoxifene 20 mg/CE 0.625 mg groups as compared 
to the respective CE-alone groups. Moreover, the changes 
in endometrial thickness for both 20 mg bazedoxifene/CE 
combinations were not statistically different from placebo. 
All doses of bazedoxifene combined with CE 0.625 mg, and 
bazedoxifene 5 mg/CE 0.3 mg, had a signiﬁ  cant reduction in 
frequency of hot ﬂ  ushes compared with all control groups. 
Amenorrhea was maintained for the duration of the study 
in 92% of placebo-treated subjects, and in 84.2% to 94.6% 
of subjects treated with bazedoxifene/CE formulations. 
Overall, these ﬁ  ndings warranted further investigation in 
different trials.
Preliminary results from multicenter randomized, 
double-blind, placebo- and active-controlled phase III 
trial of bazedoxifene/CE for the prevention of endometrial 
hyperplasia and osteoporosis in postmenopausal women have 
been recently presented as abstracts in different meetings 
(Table 2). The selective estrogen menopause and response 
to therapy 1 (SMART-1) trial was a 2-year, double-blind, 
randomized, placebo-controlled phase III study with daily 
bazedoxifene 10, 20, or 40 mg combined with CE (0.45 or 
0.625 mg) compared with raloxifene (60 mg) or placebo 
(Gallagher et al 2007; Lewis et al 2007). Participants were 
3397 postmenopausal women, aged 45–70 years. Primary 
endpoint was the incidence of endometrial hyperplasia 
at 1 year; secondary endpoints included the incidence of 
endometrial hyperplasia at 2 years, breast pain and effects 
on BMD. Increasing doses of bazedoxifene/CE resulted 
in decreasing incidences of endometrial hyperplasia. In 
particular, the doses containing bazedoxifene 20 or 40 mg 
paired with 0.45 or 0.625 mg were associated with hyper-
plasia rates at 1 year below 1.0% that did not differ from 
placebo or raloxifene (Lewis et al 2007; Pickar et al 2007). 
Cumulative amenorrhea rates for all combinations containing 
bazedoxifene 20 mg and 40 mg, and for bazedoxifene/CE 
10/0.45 mg, were not signiﬁ  cantly different than for placebo. 
Moreover, for all doses of bazedoxifene/CE the incidence 
Table 2 Clinical phase III trials of bazedoxifene in combination with conjugated estrogen
Protocol ID Duration Population Compound Primary endpoints Secondary endpoints
SMART-1 2 years Postmenopausal 
women (n = 3397)
BAZ 10, 20, 40 mg 
combined with CE (0.45 
or 0.625 mg) vs raloxifene 
60 mg or placebo
Endometrial hyperplasia 
(at 1 year)
Endometrial hyperplasia 
(at 2 years); breast pain; 
effects on BMD
SMART-2 12 weeks Postmenopausal 
women with hot 
ﬂ  ushes (n = 318)
BAZ 20 mg combined 
with CE (0.45 or 
0.625 mg) vs placebo
Moderate or severe hot 
ﬂ  ushes at week 4 or 12
Breast pain; sleep quality
SMART-3 12 weeks Postmenopausal 
women with vaginal 
atrophy (n = 652)
BAZ 20 mg combined 
with CE (0.45 or 
0.625 mg) vs BAZ 20 mg 
or placebo
Vaginal atrophy (superﬁ  cial 
and parabasal cells)
Sexual function; menopause 
related quality of life
SMART-4 2 years Postmenopausal 
women (n = 1083)
BAZ 20 mg combined 
with CE (0.45 or 0.625 mg) 
vs CE (0.45 mg)/
medroxyprogesterone 
acetate (1.5 mg) or 
Placebo
Endometrial hyperplasia 
(at 1 year); BMD change 
at 1 year (osteoporosis 
substudy)
Uterine bleeding/spotting; 
breast pain
Abbreviations: AE, adverse event; BMD, bone mineral density; BZA, bazedoxifene acetate; CE, conjugated estrogen; PB, placebo.Therapeutics and Clinical Risk Management 2008:4(6) 1238
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of breast pain was similar to placebo (Bergmann Koury 
2007; Lewiecki 2007). Taken together, these ﬁ  ndings sug-
gest that bazedoxifene/CE does not stimulate endometrial 
and breast tissue. The SMART-1 osteoporosis substudy 
enrolled 2315 postmenopausal women (861   5 years 
postmenopause and 1454   5 years postmenopause) 
(Gallagher et al 2007; Lindsay et al 2007). After 2 years, 
all bazedoxifene/CE regimens were associated with greater 
increases in lumbar BMD (range, 1.15%–2.61%) compared 
with placebo (–1.92%). Importantly, among women within 
5 years postmenopause, the mean increase from baseline in 
lumbar spine BMD at 2 years was signiﬁ  cantly greater with 
all bazedoxifene/CE doses (range, 1.15%–2.61%) compared 
with raloxifene (0.15%; p   0.05) (Figure 3a and b). Among 
women  5 years postmenopause, the increase from baseline 
in lumbar spine BMD at 2 years was signiﬁ  cantly greater 
with TSECs containing bazedoxifene 10 and 20 mg (range, 
1.57%–2.42%) than with raloxifene (0.73%; p   0.05). 
Similar results were observed for hip BMD. Moreover, 
greater suppression of bone turnover markers was observed 
with bazedoxifene/CE regimens compared with placebo 
(Bergmann Koury 2007). In two different selective estro-
gen menopause and response to therapy trials (SMART-2 
and SMART-3) the efﬁ  cacy of bazedoxifene/CE combina-
tion on vaginal dryness, hot ﬂ  ushes and other menopausal 
symptoms was investigated. In the 12-week SMART-2 
study 318 postmenopausal women with 7 or more moderate 
to severe hot ﬂ  ushes per day or 50 or more per week were 
randomized to bazedoxifene/CE 20/0.45 and 20/0.65 mg 
or placebo (Pinkerton et al 2007). All treatment groups had 
fewer hot ﬂ  ushes from baseline at all time points. However, 
bazedoxifene/CE groups had a signiﬁ  cantly greater reduction 
in the number of moderate to severe hot ﬂ  ushes at weeks 
4 and 12 compared with placebo, reaching a 74% to 80% 
decrease from baseline at week 12 (vs 51% in placebo). There 
was also a statistical signiﬁ  cant difference against placebo 
in the daily number of moderate to severe hot ﬂ  ushes in the 
bazedoxifene/CE 20/0.45 mg group from week 3 onward and 
in the bazedoxifene/CE 20/0.65 mg from week 2 onward. The 
incidence of breast pain did not differ from placebo. In addi-
tion, the bazedoxifene/CE-treated women had fewer sleep 
disturbances and improved sleep adequacy than placebo. 
The 12-week SMART-3 study was speciﬁ  cally designed to 
investigate the effects of bazedoxifene/CE on vaginal atrophy 
and sexual function in 652 postmenopausal women with 
moderate to severe vulvar/vaginal atrophy, vaginal pH   5.0 
or fewer superﬁ  cial cells (Kagan et al 2007). Participants 
were randomized to four treatment groups: bazedoxifene/CE 
20/0.45 mg and 20/0.625 mg, bazedoxifene 20 mg alone, or 
placebo. In the 601 women who completed the study, both 
the bazedoxifene/CE regimens showed increases in the 
percentage of superﬁ  cial cells and decreases in parabasal 
cells compared with placebo. All active treatment groups 
resulted in a greater decrease in vaginal pH compared with 
placebo and a greater improvement in the most bother-
some vulvar/vaginal atrophy symptom index. Moreover 
parameters of sexual function (Arizona Sexual Experiences 
Scale lubrication score and Menopause Speciﬁ  c Quality 
of Life total and sexual function scores) also improved in 
both bazedoxifene/CE doses compared with placebo. An 
additional phase III, 2-year study (SMART-4) compared 
the effects of bazedoxifene/CE (20/0.45 and 20/0.625 mg) 
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to CE/medroxyprogesterone acetate 0.45/1.5 mg or placebo 
in 1083 postmenopausal women. Primary endpoint was 
the rate of endometrial hyperplasia at 1 year. A SMART-4 
trial osteoporosis substudy was also designed. No data are 
currently available from this trial.
Side effects and contraindications
In all clinical trials bazedoxifene, given either alone or in 
combination with CE appeared to be well tolerated, with 
few patients experiencing side effects.
phase I studies of bazedoxifene alone demonstrated that 
the compound is safe, with no toxicity at doses up to 80 mg, 
signiﬁ  cantly higher than those currently used in ongoing 
phase II/III studies (Ermer et al 2000). In a phase II study 
with bazedoxifene acetate 20, 30, and 40 mg, the most 
commonly reported treatment-emergent adverse events 
were abdominal pain, headache, and ﬂ  u syndrome (Ronkin 
et al 2005). Importantly, the 40 mg bazedoxifene group 
experienced signiﬁ  cantly less breast pain than placebo 
(10.0% vs 25.4%). In phase II studies vasodilatation (hot 
ﬂ  ushes) was more common with bazedoxifene doses of 
20 and 40 mg (19.9% and 22.6%, respectively), than with 
placebo (13.2%), but similar to raloxifene (18.3%) (Chesnut 
et al 2007). Overall, two completed phase III studies 
conﬁ  rmed the favorable safety proﬁ  le of bazedoxifene 
given alone, even though with slightly different results 
(Table 3). The percentage of women who reported either 
worsening or the development of new hot ﬂ  ushes was 
higher in the bazedoxifene groups than in the placebo 
group in both studies, but similar to that observed in the 
raloxifene group. In contrast, the incidence of thrombotic 
events was low ( 1%) and similar to that with raloxifene 
or placebo in a phase III 2-year study (Chesnut et al 2007, 
Miller 2008), but slightly higher than placebo in a 3-year 
phase III study (Adachi et al 2007; Silverman et al 2008). 
The number of cases of breast cancer was low in these trials 
and did not differ from placebo or raloxifene. In all phase II 
and III studies, bazedoxifene at doses up to 40 mg did not 
stimulate the endometrium, consistent with the preclinical 
data showing anti-uterotropic activity to inhibit estrogen-
induced histological changes. Moreover, the addition of 
bazedoxifene to CE resulted in a dose-related decrease in 
endometrial thickness. Importantly, combinations of baze-
doxifene/CE also showed a beneﬁ  cial effect on vasomotor 
symptoms. In particular, bazedoxifene/CE at different 
doses signiﬁ  cantly reduced the number and severity of hot 
ﬂ  ushes when compared with placebo (Van Duren et al 2006; 
Pinkerton et al 2007). The most commonly reported side 
effects of bazedoxifene/CE in a phase II trial (SMART-3) 
were headache and joint pain, even though their frequency 
Table 3 Summary of safety proﬁ  le in phase III trials of bazedoxifene
Adverse event Miller et al 2008 Silverman et al 2008
Trial ID NCT00481169 NCT00205777
Study length (months) 24 36
Sample size (n) 1583 7492
Mean age (yrs ± SD) 57.6 ± 6.5 66.4 ± 6.7
BZA treated subjects (n) 962 3758
BZA dose range (mg) 10–40 20–40
Any AE (% vs PB) 94.4–95.3 vs 95.8 95.7–96.8 vs 96.2
Discontinuation due to AE (% vs PB) 16.8–18.2 vs 15.5 14.4–14.4 vs 12.7
Deaths (% vs PB) 0.0–0.9 vs 0.3 0.7–0.9 vs 0.6
Hot ﬂ  ushes (% vs PB) 19.6–24.1 vs 14.2 (p   0.05) 12.6–13.0 vs 6.3 (p   0.001)
Leg cramps (% vs PB) 9.3–12.1 vs 11.6 10.9 vs 8.2 (p   0.01)
Stroke (% vs PB) 0.0–0.3 vs 0.3 1.0 vs 1.1
Deep venous thrombosis (% vs PB) 0.0–0.6 vs 0.3 0.4–0.5 vs 0.1 (p   0.05)
Pulmonary embolous (% vs PB) 0.0–0.3 vs 0.0 0.2–0.3 vs 0.2
Breast cancer (% vs PB) 0.3–0.6 vs 0.6 0.2–0.3 vs 0.4
Fibrocystic breast disease (% vs PB) - 0.6–0.7 vs 1.0
Endometrial cancer (% vs PB) 0.0 vs 0.3 0.0–0.1 vs 0.2
Endometrial hyperplasia (% vs PB) - 0.1 vs 0.1
Abbreviations: AE, adverse event; BZA, bazedoxifene acetate; PB, placebo.Therapeutics and Clinical Risk Management 2008:4(6) 1240
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was not signiﬁ  cantly different from placebo. No speciﬁ  c 
contraindications have been described for the compound, 
given either alone or in combination with CE.
Conclusions and future directions
Tissue selectivity is a fundamental component to the 
functional application of SERMs for the prevention and 
treatment of osteoporosis. Optimally, an ideal SERM would 
exhibit the positive attributes associated with HRT, which 
include skeletal protection, reduction of vasomotor symptoms 
and of vaginal atrophy, but also would not stimulate the 
uterus or the breast as seen with long term HRT. Additional 
beneﬁ  ts of the ideal compound would be a neutral or positive 
effect on cognition (particularly in regard to Alzheimer’s 
disease) and a positive action on cardiovascular system. 
Even though currently available SERMs, tamoxifen and 
raloxifene have the potential to retain most of the beneﬁ  cial 
effects of estrogen avoiding some of its adverse events, they 
are also responsible for side effects such as thromboembolic 
disorders, vasomotor symptoms and, concerning tamoxifen, 
uterine cancer. These contraindications represent a major 
concern especially for the type of long-term, chronic therapy 
that is required to prevent osteoporosis. Moreover, both 
preclinical and clinical reports suggest that these SERMs 
are considerably less potent than estrogen.
Bazedoxifene is a novel, stringently screened SERM that 
has been speciﬁ  cally designed as a preventive therapy for 
postmenopusal osteoporosis, without stimulating the uterus 
or the breast (Komm et al 2001). Like other SERMs, such 
as tamoxifen and raloxifene, bazedoxifene targets estrogen 
receptors leading to selective inhibition or stimulation of 
estrogen-like action in target tissues. Both preclinical and 
clinical data indicate that this SERM has a unique combina-
tion of attributes, making it an extremely attractive alternative 
for the treatment and prevention of osteoporosis.
In both preclinical and clinical studies this SERM showed 
a unique effect on the endometrium, with respect to the current 
available SERMs. Indeed, endometrial effects have been a 
focal point in the development of recent SERMs. Tamoxifen 
is known to cause endometrial proliferation and to increase 
endometrial cancer risk. The clinical development of different 
new SERMs such as idoxifene and levormeloxifene has been 
halted, partially due to their stimulatory effects on the uterus. 
In this context, bazedoxifene represents a clear improvement in 
this ﬁ  eld (Ronkin et al 2005). In fact, no other SERM, including 
raloxifene, has been shown in preclinical and clinical studies 
to have antagonistic activity in the endometrium (Komm et al 
2001; Ronkin et al 2005). Moreover, in phase III clinical trials 
of postmenopausal women this compound, at doses ranging 
from 20 to 60 mg/day, demonstrated beneﬁ  cial skeletal effects 
increasing BMD and preventing the occurrence of vertebral 
fractures compared to placebo, and with a similar efﬁ  cacy 
than raloxifene. Indeed, treatment regimens with different 
compounds such bisphosphonates are known to produce a more 
pronounced increase in BMD when compared with all SERMs, 
including bazedoxifene (Liberman et al 1995; Hosking et al 
1998; Ettinger et al 1999). However, the similar reductions 
in vertebral fracture rates seen with raloxifene, bazedoxifene 
and bisphosphonates in non head-to-head trials indicate that a 
greater increase in BMD does not necessarily correlate with 
a greater improvement of bone strength (Delmas and Seeman 
2004; Seeman and Delmas 2006). Thus, different components 
of bone strength (ie, bone material properties and/or microar-
chitecture), not captured by changes in BMD, may contribute 
to the reduction in fracture risk observed with SERMs such as 
raloxifene and bazedoxifene. Moreover, a potentially increased 
effect on nonvertebral fracture prevention of bazedoxifene over 
placebo and raloxifene (at least in women at higher fracture 
risk) has been also shown (Silverman et al 2008), even though 
further studies are needed to conﬁ  rm this issue. Overall, these 
data suggest that bazedoxifene may have a role in the treatment 
of postmenopausal osteoporosis. Based on promising results of 
phase III studies, bazedoxifene acetate is currently under FDA 
revision for the prevention and treatment of osteoporosis. An 
approvable FDA letter for prevention has already been released 
on April 2007, even though further analysis and discussion 
concerning the incidence of stroke and of venous thrombotic 
events have been advised. Indeed, the latter points constitute 
the major concerns about long term treatment with SERMs. 
Even though the overall incidence of venous thromboembolism 
in the active bazedoxifene treatment groups was very low in 
both phase III trials (below 1%), it was signiﬁ  cantly higher than 
placebo in one study (Silverman et al 2008). Further, long-term 
studies are needed to fully address this issue. In addition, fewer 
cases of breast cancer were reported in bazedoxifene treatment 
groups compared with the placebo and raloxifene groups, which 
may indicate a protective effect on breast cancer as has been 
shown with other SERMs. This issue also needs to be further 
investigated in breast cancer prevention trials, in order to fully 
understand the therapeutic potential of this new SERM.
Importantly, more recent clinical investigation has lead 
to the development of the ﬁ  rst compound of a new class of 
menopausal therapy called TSEC, in which bazedoxifene 
has been combined with CE. Theoretically, this combina-
tion creates a compound with more balanced “estrogenic” 
response, that could potentially maximize drug beneﬁ  ts Therapeutics and Clinical Risk Management 2008:4(6) 1241
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while minimizing adverse effects. This hypothesis seems 
to be conﬁ  rmed by preliminary and yet unpublished data 
from phase III clinical trials that demonstrated a poten-
tially improved skeletal proﬁ  le of bazedoxifene/CE over 
raloxifene, in terms of BMD gain. Together with its favor-
able endometrial safety proﬁ  le and improved efﬁ  cacy for 
vasomotor symptoms the clinical proﬁ  le of bazedoxifene/CE 
may change the way women and physicians approach meno-
pausal symptoms. Thus, this treatment would particularly 
beneﬁ  t postmenopausal women who suffer severe vasomotor 
symptoms and require bone protection. However, notwith-
standing the encouraging and innovative preclinical and 
clinical evidences, available data from phase III trials are very 
limited and the efﬁ  cacy of bazedoxifene/CE in the prevention 
of osteoporotic fractures remains unknown, as well as the 
optimal dosage for this combination. At the moment, insuf-
ﬁ  cient clinical data and the lack of detailed information on 
long-term efﬁ  cacy or possible side effects (ie, thromboem-
bolic disorders) preclude a reasonable prediction of the future 
of this promising tissue selective estrogen complex.
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